NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Nucleus Genomics

Nucleus Genomics

Private
New York City, New YorkHealthcare & Life Scienceshttps://nucleusgenomics.com/

Last Round

Series A

Jan 30, 2025

Total Funding Raised

$31.5M

Company Overview

Nucleus Genomics is a biotechnology company that provides direct-to-consumer whole-genome sequencing and analysis for health risks, family planning, and preventative health.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Biotechnology, D2C Brands, Healthcare Analytics

Business Model

B2C

Customer Profile

Hardware Sales, Subscription SaaS, Services & Consulting

AI Layer

Application

Keywords

whole-genome sequencingWGSpolygenic risk scoreDTC genetic testingconsumer genomicsat-home DNA testembryo analysispreimplantation genetic testingPGTPRSIVF genetic testingcarrier screeningpersonalized medicinepreventive healthrare variant analysisDNA data uploadB2B2C healthcare

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nucleus Genomics Comparables

Compare Nucleus Genomics with similar companies based on industry and business-model similarity.

Nucleus Genomics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Nucleus Genomics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 30, 2025
SeedJul 14, 2022
Pre SeedDec 15, 2021

Nucleus Genomics Investors

Notable investors and investment history

Nucleus Genomics investors
InvestorRounds
Rose Street CapitalSeries A
NeoSeries A
Founders FundSeed, Series A, Pre Seed
Asylum VenturesSeries A
Seven Seven SixSeed, Series A
Common MetalSeries A
Samsung Next TLVSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 30, 2025

    $14M round led by Founders Fund and Seven Seven Six.

  • Jul 14, 2022

    $14M round led by Seven Seven Six.

Nucleus Genomics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nucleus Genomics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nucleus Genomics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Year Founded2020
Last FundingJan 30, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.